Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer

Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) prolongs overall survival in men with metastatic castration-resistant prostate cancer (mCRPC). However, men with low PSMA expression are excluded from RLT. We explored the effect of androgen receptor blockade with enzalutam...

Full description

Bibliographic Details
Main Authors: Magdalena Staniszewska, Pedro Fragoso Costa, Matthias Eiber, Jasmin M. Klose, Jasmin Wosniack, Henning Reis, Tibor Szarvas, Boris Hadaschik, Katharina Lückerath, Ken Herrmann, Wolfgang P. Fendler, Janette Iking
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:International Journal of Molecular Sciences
Subjects:
PSMA
prostate cancer
enzalutamide
androgen receptor blockade
PET
CT
Online Access:https://www.mdpi.com/1422-0067/22/14/7431

Internet

https://www.mdpi.com/1422-0067/22/14/7431

Similar Items